ShareValue scores for PRM.LSE: Valuation 49, Quality 46, Growth 40, Health 50.

PRM.LSE
LSE

Proteome Sciences PLC

£0.02(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
49
Fair Value
Price vs Value
Quality
46
Moderate
Business Strength
Growth
40
Weak
Revenue & Earnings
Health
50
Moderate
Financial Stability
Momentum
74
Bullish
Price Trend

Company Details

About

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM); SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. Proteome Sciences plc was incorporated in 1993 and is based in Cobham, the United Kingdom. Address: Coveham House, Cobham, United Kingdom, KT11 3EP

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026